Literature DB >> 8673041

Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation.

J E Talmadge1, E C Reed, A Kessinger, C A Kuszynski, G A Perry, C L Gordy, K C Mills, M L Thomas, S J Pirruccello, B A Letheby, M A Arneson, J D Jackson.   

Abstract

The immunologic attributes of cytokine mobilized peripheral blood stem cell (PSC) products (n = 52) and the resulting reconstitution of the hematopoietic and immunologic system following autologous transplantation were examined in a consecutive population of non-Hodgkin lymphoma (NHL), or solid tumor patients at the University of Nebraska Medical Center. Granulocyte-monocyte colony stimulating factor (GM-CSF)-mobilized PSC products had a high frequency of monocytes (31%) and bands (15%) as compared to normal peripheral blood (PB) cells. The phenotypic analysis of the mobilized PSC product revealed that they had normal levels of CD4+ cells, an increased frequency of CD8+ cells and a corresponding decrease in the CD4+:CD8+ cell ratio as compared to the peripheral blood leukocytes (PBL) of normal individuals. PSC products also had an increase in CD34+ cells as compared to PB. Natural killer (NK) and T cell activity in the PSC products were also lower than that observed in PB. Post-transplantation there was an accelerated reconstitution of NK-cell function in the PB as compared to T cell function (PHA (phytohemagglutinin) mitogenesis) which did not return to normal by day 100 post-transplantation. We also report for the first time high levels of an irradiation resistant suppressor cell activity in the PSC product and in the PB post-transplantation. There was also a concomitant increase in CD4-, CD8-, TCR alpha/beta+ cells (phenotypic homolog of 'natural suppressor' (NS) cells) in the PB post-transplantation. The number of months of prior chemotherapy correlated with PHA response but the NS activity and frequency of CD4-, CD8- and TCR alpha/beta+ cells did not. Further, cytokine mobilization and apheresis appears to contribute to the loss of PHA responsiveness and the increased levels of suppressor cell activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8673041

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

1.  HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.

Authors:  Ann Woolfrey; John P Klein; Michael Haagenson; Stephen Spellman; Effie Petersdorf; Machteld Oudshoorn; James Gajewski; Gregory A Hale; John Horan; Minoo Battiwalla; Susana R Marino; Michelle Setterholm; Olle Ringden; Carolyn Hurley; Neal Flomenberg; Claudio Anasetti; Marcelo Fernandez-Vina; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-24       Impact factor: 5.742

2.  Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected.

Authors:  Kenneth R Meehan; Laleh Talebian; Jillian Wu; John M Hill; Zbigniew M Szczepiorkowski; Charles L Sentman; Marc S Ernstoff
Journal:  Cytotherapy       Date:  2010-09-27       Impact factor: 5.414

Review 3.  Phenotype, development, and biological function of myeloid-derived suppressor cells.

Authors:  Yang Zhao; Tingting Wu; Steven Shao; Bingyi Shi; Yong Zhao
Journal:  Oncoimmunology       Date:  2015-10-14       Impact factor: 8.110

Review 4.  Role of myeloid-derived suppressor cells in metastasis.

Authors:  Kathryn Cole; Kristina Pravoverov; James E Talmadge
Journal:  Cancer Metastasis Rev       Date:  2021-01-07       Impact factor: 9.264

5.  Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.

Authors:  J Wang; T R McGuire; H C Britton; J K Schwarz; F R Loberiza; J L Meza; J E Talmadge
Journal:  Clin Exp Metastasis       Date:  2015-01-25       Impact factor: 5.150

Review 6.  Myeloid-derived suppressor cells (MDSCs) in brain cancer: challenges and therapeutic strategies.

Authors:  Mohammad Salemizadeh Parizi; Fatemeh Salemizadeh Parizi; Saeed Abdolhosseini; Shohreh Vanaei; Ali Manzouri; Farnoosh Ebrahimzadeh
Journal:  Inflammopharmacology       Date:  2021-10-06       Impact factor: 4.473

7.  Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products.

Authors:  Rakesh K Singh; Michelle L Varney; Cheryl Leutzinger; Julie M Vose; Philip J Bierman; Suleyman Buyukberber; Kazuhiko Ino; Kevin Loh; Craig Nichols; David Inwards; Robert Rifkin; James E Talmadge
Journal:  Int Immunopharmacol       Date:  2007-04-20       Impact factor: 4.932

Review 8.  History of myeloid-derived suppressor cells.

Authors:  James E Talmadge; Dmitry I Gabrilovich
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

Review 9.  Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Authors:  Sarah A Holstein; Zaid Al-Kadhimi; Luciano J Costa; Theresa Hahn; Parameswaran Hari; Jens Hillengass; Allison Jacob; Nikhil C Munshi; Stefania Oliva; Marcelo C Pasquini; Qian Shi; Edward A Stadtmauer; Stephanie L Waldvogel; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-14       Impact factor: 5.742

Review 10.  The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD).

Authors:  Christos Demosthenous; Ioanna Sakellari; Vassiliki Douka; Penelope Georgia Papayanni; Achilles Anagnostopoulos; Eleni Gavriilaki
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.